trastuzumab deruxtecan Dec 7, 2022 Enhertu Shows Activity in Early-Stage HER2-Low Breast Cancer Patients in Study Reported at SABCS Nov 14, 2022 EMA's CHMP Recommends Enhertu for HER2-Positive Gastric Cancer Nov 10, 2022 AstraZeneca Q3 Revenues From Oncology Products Grow 20 Percent Premium Oct 4, 2022 FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients Aug 12, 2022 AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer Aug 9, 2022 GSK, Mersana Therapeutics Ink $100M Option Agreement for Antibody-Drug Conjugate Aug 5, 2022 FDA Approves Enhertu for HER2-Low Metastatic Breast Cancer Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 19, 2022 Enhertu Racks Up Another EU Approval in Second-Line HER2-Positive Metastatic Breast Cancer Jul 18, 2022 Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer Jun 27, 2022 EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications May 26, 2022 UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients Premium May 11, 2022 Strata Oncology Enrolling Patients in Basket Trial Exploring Biomarker-Defined Indications Apr 29, 2022 AstraZeneca Q1 Oncology Product Sales Increase 14 Percent Led by Tagrisso Apr 9, 2022 Jury in Enhertu Patent Infringement Case Orders Daiichi Sankyo to Pay $41.8M in Damages Feb 22, 2022 AstraZeneca, Daiichi Sankyo to Begin Regulatory Talks to Expand Enhertu Into HER2-Low Breast Cancer Feb 10, 2022 AstraZeneca Q4 Oncology Revenues Grow 20 percent Jan 21, 2022 In Brief This Week: AstraZeneca, Daiichi Sankyo, Orgenesis, Amgen Jan 18, 2022 AstraZeneca, Daiichi Sankyo File for FDA Enhertu Approval in Second-Line HER2-Postive Breast Cancer Dec 28, 2021 EMA to Review Daiichi Sankyo, AstraZeneca's Enhertu For Second-Line HER2-Positive Breast Cancer Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
